The biotech sector recently experienced a sharp reversal following a failed breakout attempt post-election. While most areas of the market surged to new heights after Donald Trump’s election win on November 5, biotech ETFs like the iShares Biotechnology ETF (NASDAQ: IBB) and the SPDR Biotech ETF (NYSE: XBI) stopped short of new 52-week highs. This false breakout has sparked significant selling, leaving investors questioning whether this represents a buying opportunity or a reason to exit the sector entirely. Let’s dive deeper into the developments.
